NCT03846843View on ClinicalTrials.gov

OCR002-SP103 - Oral Immediate Release Study

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 15, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

December 31, 2017

Conditions
Cirrhosis
Interventions
DRUG

OCR-002 IR Oral Tablet

OCR-002 3 gram immediate release (IR) tablet for oral administration

DRUG

OCR-002 Oral Solution

OCR-002 5 gram solution for oral administration

DRUG

OCR-002 IV Solution

OCR-002 5 gram solution for intravenous (IV ) administration

Trial Locations (1)

92118

Southern California Research Center, Coronado

Sponsors
All Listed Sponsors
lead

Ocera Therapeutics, Inc.

INDUSTRY

NCT03846843 - OCR002-SP103 - Oral Immediate Release Study | Biotech Hunter | Biotech Hunter